US 12,252,547 B2
Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
Mira Peled Kamar, Herzlia (IL); Galit Denkberg, Nofit (IL); Yoram Reiter, Haifa (IL); Ilan Beer, Haifa (IL); Keren Sinik, Ramat-Yishai (IL); Yael Teboul (Elbaz), Haifa (IL); Yael Shperber (Sery), Kfar-Vradim (IL); Reut Erel Segal, Haifa (IL); Ravit Oren, Haifa (IL); and Dror Shmuel Alishekevitz, Kiryat-Tivon (IL)
Assigned to ADICET THERAPEUTICS, INC., Redwood City, CA (US)
Filed by ADICET THERAPEUTICS, INC., Redwood City, CA (US)
Filed on May 11, 2021, as Appl. No. 17/317,824.
Application 17/317,824 is a division of application No. 15/579,616, granted, now 11,001,642, previously published as PCT/IL2016/050600, filed on Jun. 8, 2016.
Claims priority of application No. N2014935 (NL), filed on Jun. 8, 2015.
Prior Publication US 2021/0388111 A1, Dec. 16, 2021
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3053 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); G01N 33/5743 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); G01N 33/57492 (2013.01)] 16 Claims
 
1. An affinity binding entity comprising an antigen binding domain comprising:
(i) CDR sequences of an immunoglobulin heavy chain which are N—C ordered:
 
 CDR1 HC
 
 SEQ ID NO: 341
 
 GYWIE
 
 
 
 CDR2 HC
 
 SEQ ID NO: 342
 
 EILPGSGGTNYNEKFKG
 
 
 
 CDR3 HC
 
 SEQ ID NO: 343
 
 DSNSFTY;
and
(ii) CDR sequences of an immunoglobulin light chain which are N—C ordered:
 
 CDR1 LC
 
 SEQ ID NO: 335
 
 SVSSSVDYIH
 
 
 
 CDR2 LC
 
 SEQ ID NO: 336
 
 STSILAS
 
 
 
 CDR3 LC
 
 SEQ ID NO: 337
 
 QQRSSYPPT,
wherein said affinity binding entity is capable of binding HLA-A2/MAGE-A4230-239 in an MHC restricted manner.